Boston Scientific’s Trading Volume Plummets to 145th as Regulatory Shifts and Partnership Exit Fuel Uncertainty

On September 22, 2025, , . , .

Recent developments affecting BSX include a regulatory update from the FDA regarding potential revisions to its medical device approval process. While no immediate operational adjustments were announced, . .

Separately, a partnership dissolution between BSX and a European research consortium has drawn attention. , which focused on cardiac rhythm management technologies, . .

Back-test parameters require clarification prior to execution: The investment universe must define whether all U.S. stocks or a specific index will be included. . , , . .